|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:affiliatedWith
|
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AG03
|
|
gptkbp:bioavailability
|
40-45%
|
|
gptkbp:brand
|
gptkb:Stocrin
gptkb:Sustiva
|
|
gptkbp:CASNumber
|
gptkb:154598-52-4
|
|
gptkbp:combines
|
gptkb:lamivudine
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
pregnancy (first trimester)
|
|
gptkbp:developedBy
|
gptkb:DuPont
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:eliminationHalfLife
|
40-55 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C14H9ClF3NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Efavirenz
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:phenytoin
gptkb:carbamazepine
gptkb:St._John's_wort
|
|
gptkbp:KEGGID
|
D00821
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:MedlinePlusID
|
a699004
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
99.5%
|
|
gptkbp:PubChem_CID
|
CHEMBL122
57718
64139
DB00625
|
|
gptkbp:riskFactor
|
teratogenicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
dizziness
rash
hepatotoxicity
insomnia
impaired concentration
vivid dreams
|
|
gptkbp:UNII
|
JE6H2O27P8
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:EFV
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|